SEER
Biotechnology · Healthcare
Equibles does not estimate personal net worth.
Get an email with a short summary when Seer, Inc. publishes a filing, an earnings call transcript or a press release.
Get SEER alertsSeer, Inc. reported in an 8-K filed September 18, 2026 that David Horn resigned as President, Chief Financial Officer and Treasurer, effective October 1, 2026. The proxy statement of Seer, Inc. reports total compensation of $1,428,020 for David Horn in fiscal 2024, including a base salary of $525,888. Disclosed compensation is on record for 5 fiscal years. David Horn has spoken on 23 earnings calls across 1 company, most recently for Seer, Inc. on August 11, 2026. Seer, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Seer, Inc. includes Omid Farokhzad (CEO and Board Member), Charles Endweiss (CFO and Chief Accounting Officer), Elona Kogan (General Counsel) and 7 others.
“On September 14, 2026, David Horn resigned as the President, Chief Financial Officer and Treasurer of Seer, Inc. (the "Company") to pursue other interests, effective as of October 1, 2026.”
“Total revenue for the second quarter of 2026 was $3.1 million compared to $4.1 million in the second quarter of 2025 and to $2.8 million in the first quarter of 2026.”
“Total revenue for the first quarter of 2026 was $2.8 million, compared to $4.2 million in the first quarter of 2025.”
“Turning to slide 7, total revenue for the fourth quarter of 2025 was $4.2 million, representing an increase of 5% compared to $4 million in the fourth quarter of 2024, and was primarily due to higher product revenue.”
“Total revenue for the third quarter of 2025 was $4.1 million, representing an increase of 2% compared to $4 million in the third quarter of 2024. It was primarily due to higher product and service revenue.”
“Total revenue for the second quarter of 2025 was $4.1 million, representing an increase of 32% compared to $3.1 million in the second quarter of 2024 and was primarily due to higher product and service revenue.”
SEC 8-K
2023-11-17–present
Start not stated–2026-10-01
SEER
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Seer, Inc. (SEER) | President and Chief Financial Officer | $525,888 | $1,428,020 |
| 2023 | Seer, Inc. (SEER) | Chief Financial Officer and President | $461,250 | $1,450,396 |
| 2022 | Seer, Inc. (SEER) | Chief Financial Officer and President | $427,166 | $2,925,251 |
| 2021 | Seer, Inc. (SEER) | Chief Financial Officer | $389,982 | $3,880,242 |
| 2020 | Seer, Inc. (SEER) | Chief Financial Officer | $227,269 | $4,263,439 |